Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB26FUJLY
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of Xtandi 80 mg on October 21, 2025. Valued at $4,169.59 under a firm fixed-price arrangement, this delivery order was issued without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award was executed under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which carries a $499,999,999 ceiling value and extends through December 31, 2036.
Xtandi is a specialized oncology pharmaceutical used in the treatment of prostate cancer, reflecting the broad therapeutic portfolio that DMS Pharmaceutical Group supplies to Department of Defense medical facilities worldwide. The PPV-G GEN V program, part of a larger $30.3 billion acquisition strategy, establishes multiple regional prime vendor contractors to support recurring pharmaceutical and medical supply needs across the global military healthcare system. This delivery order represents routine execution of the underlying IDC, enabling the Defense Logistics Agency to procure specialized pharmaceuticals efficiently to maintain critical medical supply operations for military personnel and beneficiaries.
Quick answers
Who was awarded contract SPE2DB26FUJLY?
SPE2DB26FUJLY was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 21, 2025.
How much is contract SPE2DB26FUJLY worth?
The government has obligated $4,170 on SPE2DB26FUJLY.
Is contract SPE2DB26FUJLY an order under another contract?
Yes. SPE2DB26FUJLY is a delivery order under SPE2DB25D9365, an indefinite delivery contract.
Was contract SPE2DB26FUJLY competed?
The extent of competition for SPE2DB26FUJLY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award